Biotech Stocks Find Reprieve in Options
Jan 5, 2017 12:57 pm ET 
 
After the worst year for American biotechnology stock since 2002, options traders are optimistic about the group, according to data compiled by In a note Thursday, the firm showed how options positioning for two biotech exchange-traded funds was among the most positive. The skews — the differences between prices of options — for the ETF […]
 To Read the Full Story
